Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681137 | 0.82 | ADRB2 (0.42) | LMNASMN1; SMN2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL12193936 | 0.81 | ALDH1A1 (0.43) | AKR1C3AKR1C2ALDH1A1LMNAHTT | |
| SCHEMBL681170 | 0.81 | ALDH1A1 (0.43) | AKR1C3AKR1C2ALDH1A1LMNAHTT | |
| SCHEMBL681176 | 0.79 | ALDH1A1 (0.44) | AKR1C3AKR1C2ALDH1A1LMNAHTT | |
| SCHEMBL14304005 | 0.77 | ALDH1A1 (0.42) | AKR1C3AKR1C2ALDH1A1LMNAHTT | |
| SCHEMBL14308721 | 0.76 | ALDH1A1 (0.46) | AKR1C3AKR1C2ALDH1A1LMNAHTT | |
| SCHEMBL684406 | 0.76 | ALDH1A1 (0.46) | AKR1C3AKR1C2ALDH1A1LMNAHTT | |
| SCHEMBL8225216 | 0.73 | LMNA (0.44) | AKR1C3AKR1C2ALDH1A1LMNAHTT | |
| SCHEMBL17424876 | 0.73 | LMNA (0.44) | AKR1C3AKR1C2ALDH1A1LMNAHTT | |
| SCHEMBL684414 | 0.73 | SLC6A2 (0.49) | AKR1C3AKR1C2ALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150191479-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8846681-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8329701-B2 | Dihydrofuro pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8003651-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191479-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DPYD, DTYMK, PIK3CA | AKR1C3 1782/4885AKR1C2 1098/4885ALDH1A1 2418/4885 |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKR1C3 828/4885AKR1C2 737/4885ALDH1A1 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.